[go: up one dir, main page]

DK3486233T3 - Dårligt opløseligt kompleks eller solvat deraf, farmaceutisk sammensætning og anvendelse deraf - Google Patents

Dårligt opløseligt kompleks eller solvat deraf, farmaceutisk sammensætning og anvendelse deraf Download PDF

Info

Publication number
DK3486233T3
DK3486233T3 DK18777940.0T DK18777940T DK3486233T3 DK 3486233 T3 DK3486233 T3 DK 3486233T3 DK 18777940 T DK18777940 T DK 18777940T DK 3486233 T3 DK3486233 T3 DK 3486233T3
Authority
DK
Denmark
Prior art keywords
solvat
dissolvable
badly
complex
pharmaceutical composition
Prior art date
Application number
DK18777940.0T
Other languages
English (en)
Inventor
Shanchun Zhang
Yihua Wang
Jiashi Peng
Kaisheng Cheng
Xiao Wang
Shu Gao
Hongzhang Sun
Xiaorong Lu
Original Assignee
Fruithy Holdings Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fruithy Holdings Ltd filed Critical Fruithy Holdings Ltd
Application granted granted Critical
Publication of DK3486233T3 publication Critical patent/DK3486233T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A61K31/245Amino benzoic acid types, e.g. procaine, novocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542Carboxylic acids, e.g. a fatty acid or an amino acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00Anaesthetics
    • A61P23/02Local anaesthetics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C65/00Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C65/01Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups
    • C07C65/105Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups polycyclic
    • C07C65/11Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups polycyclic with carboxyl groups on a condensed ring system containing two rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
DK18777940.0T 2017-03-27 2018-03-26 Dårligt opløseligt kompleks eller solvat deraf, farmaceutisk sammensætning og anvendelse deraf DK3486233T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201710188001 2017-03-27
PCT/CN2018/080424 WO2018177232A1 (zh) 2017-03-27 2018-03-26 难溶性复合物或其溶剂合物、药物组合物及其应用

Publications (1)

Publication Number Publication Date
DK3486233T3 true DK3486233T3 (da) 2021-03-15

Family

ID=63675241

Family Applications (1)

Application Number Title Priority Date Filing Date
DK18777940.0T DK3486233T3 (da) 2017-03-27 2018-03-26 Dårligt opløseligt kompleks eller solvat deraf, farmaceutisk sammensætning og anvendelse deraf

Country Status (18)

Country Link
US (1) US11084790B2 (da)
EP (1) EP3486233B1 (da)
JP (1) JP6923122B2 (da)
KR (1) KR102248445B1 (da)
CN (1) CN109996787B (da)
AU (1) AU2018241564B2 (da)
CA (1) CA3049220C (da)
DK (1) DK3486233T3 (da)
EA (1) EA039449B1 (da)
ES (1) ES2866401T3 (da)
HU (1) HUE053472T2 (da)
MY (1) MY199896A (da)
PH (1) PH12019501560B1 (da)
PL (1) PL3486233T3 (da)
PT (1) PT3486233T (da)
SG (1) SG11201906132UA (da)
TW (1) TWI740045B (da)
WO (1) WO2018177232A1 (da)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110483372A (zh) * 2018-05-14 2019-11-22 南京诺瑞特医药科技有限公司 布比卡因的盐
CN111983052B (zh) * 2020-07-24 2023-03-31 合肥诺明药物安全研究有限公司 一种hyr-pb21有效成分血药浓度的定量分析方法
KR102741835B1 (ko) 2022-03-11 2024-12-12 한국한의약진흥원 등검은말벌독에 함유된 세로토닌의 안정성을 유지하기 위한 조성물
CN118566394A (zh) * 2024-08-01 2024-08-30 山东省食品药品检验研究院 一种曲安奈德混悬注射液的流通池溶出度测定方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003099293A1 (en) * 2002-05-23 2003-12-04 Danmarks Farmaceutiske Universitet Pharmacologically active salts
US20070110804A1 (en) * 2003-06-20 2007-05-17 Royer Biomedical, Inc. Drug polymer complexes
CA2581287C (en) * 2004-09-17 2015-08-25 Durect Corporation Sustained local anesthetic composition containing bupivacaine and saib
EP2209450A4 (en) 2007-11-07 2013-09-25 Svip5 Llc SLOW RELEASE OF LOCAL ANESTHESIC ORGANIC SALTS FOR PAIN RELIEF
EP2398468B1 (en) 2009-02-17 2016-11-30 KRKA, D.D., Novo Mesto Pharmaceutical compositions comprising prasugrel base or its pharmaceutically acceptable acid addition salts and processes for their preparation
CZ2009762A3 (cs) 2009-11-16 2011-05-25 Zentiva, K. S. Nové soli 5-[2-cyklopropyl-1-(2-fluorfenyl)-2-oxoethyl]-4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl acetátu známého pod nechráneným názvem prasugrel a zpusob jejich výroby
CN104370934B (zh) * 2013-08-13 2018-04-06 上海科胜药物研发有限公司 一种普拉格雷盐及其制备方法
CN107848973A (zh) * 2015-09-01 2018-03-27 四川海思科制药有限公司 S‑(‑)‑1‑丙基‑2’,6’‑二甲苯胺甲酰基哌啶晶体及其缓释制剂
IL290150B2 (en) * 2016-12-26 2024-03-01 Cellix Bio Private Ltd Compositions and methods for the treatment of chronic pain

Also Published As

Publication number Publication date
TWI740045B (zh) 2021-09-21
JP2020515513A (ja) 2020-05-28
EP3486233A4 (en) 2020-04-08
KR102248445B1 (ko) 2021-05-04
EP3486233B1 (en) 2021-01-27
SG11201906132UA (en) 2019-10-30
HUE053472T2 (hu) 2021-06-28
EA201990419A1 (ru) 2019-09-30
AU2018241564A1 (en) 2019-05-30
PH12019501560B1 (en) 2023-09-27
PL3486233T3 (pl) 2021-06-28
PT3486233T (pt) 2021-03-18
US11084790B2 (en) 2021-08-10
PH12019501560A1 (en) 2020-02-24
ES2866401T3 (es) 2021-10-19
WO2018177232A1 (zh) 2018-10-04
EP3486233A1 (en) 2019-05-22
US20210087144A1 (en) 2021-03-25
CA3049220A1 (en) 2018-10-04
AU2018241564B2 (en) 2020-07-02
CN109996787B (zh) 2022-07-05
EA039449B1 (ru) 2022-01-28
KR20190101980A (ko) 2019-09-02
JP6923122B2 (ja) 2021-08-18
MY199896A (en) 2023-11-28
CN109996787A (zh) 2019-07-09
TW201940170A (zh) 2019-10-16
CA3049220C (en) 2022-03-29

Similar Documents

Publication Publication Date Title
DK3453707T3 (da) Benzazepinderivat, fremgangsmåde til fremstilling, farmaceutisk sammensætning og anvendelse deraf
DK3557998T3 (da) Sammensætninger, kompositioner og anvendelsesmetoder
DK3580561T3 (da) Hla-baserede metoder, sammensætninger og anvendelse heraf
DK3357513T3 (da) Farmaceutisk sammensætning og anvendelse deraf
HUE055838T2 (hu) Amfifil poliszacharid-származékok és azokat tartalmazó készítmények
DK3610005T3 (da) Peptidligase og anvendelse deraf
HUE053908T2 (hu) Amid-szubsztituált piridiniltriazol-származékok és alkalmazásuk
DK3209308T3 (da) Aktiverede bifidobakterier og fremgangsmåder til anvendelse deraf
DK3298043T3 (da) SIRP-polypeptidsammensætninger og fremgangsmåder til anvendelse
DK3214081T3 (da) Isoindolinderivat, mellemprodukt, fremgangsmåde til fremstilling, farmaceutisk sammensætning og anvendelse deraf
HUE052095T2 (hu) Keratin kezelési készítmények és eljárások
DK3234133T3 (da) Crispr-baserede sammensætninger og fremgangsmåder til anvendelse
DK3209681T3 (da) Farmaceutiske sammensætninger omfattende peptidvarianter og fremgangsmåder til anvendelse deraf
HUE057607T2 (hu) Pirazol-pirimidin-származék és annak felhasználása
DK3559000T3 (da) Benzimidazol-derivater, fremgangsmåder til fremstilling og anvendelser deraf
DK3018183T3 (da) Halogenolefinbaseret sammensætning og anvendelse deraf
DK3236991T3 (da) Fgf21-derivater og anvendelser deraf
HUE055199T2 (hu) Oxiszterolok és alkalmazási eljárásaik
DK3430129T3 (da) Kolonidannende medium og anvendelse deraf
DK3233111T3 (da) Farmaceutisk sammensætning, der omfatter plasminogen, og anvendelser deraf
HUE063120T2 (hu) LRRC33-inhibitorok és alkalmazásuk
DK3612579T3 (da) Pultrudat, fremstilling og anvendelse heraf
HUE070649T2 (hu) Benzimidazol-származékok és felhasználásuk
DK3321279T3 (da) Exenatidmodificeringsmiddel og anvendelse deraf
DK3236934T3 (da) Farmaceutisk sammensætning, fremstilling og anvendelser deraf